ARCHIVES

FDA Accepts DCT Board’s Criteria For Approval Of New Drugs, Explains Plan for Early Action

This article is from The Cancer Letter archive.

Vol. 15 No. 07 | February 17, 1989

Download PDF Visit The Full Archive

Related Articles

Caris Life Sciences Lays Off Estimated 20 Percent of Staff

October 24, 2014

IOM Reports Says HIPPA Privacy Rule Hinders Research, Doesn’t Protect Patient Privacy

February 6, 2009

SWOG Opens Phase II Trial Of CuraGen’s HDAC Inhibitor For B-Cell Lymphoma

September 29, 2006

“NIH Reveres, Honors, respects And Defends One And Only One Mechanisms’ – R01s

September 20, 1991

Senate Confirms McClellan For FDA

October 25, 2002

Eppley Contract Renewed; To Be Recompeted

January 20, 1978